Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by SkywalkerofLukeon Apr 05, 2023 4:04pm

172 Views

Post# 35381801

AGN Completed 2nd Cohort of Phase 1 DMT Study

AGN.c recently announced they completed the second cohort in its escalating dose Phase 1 clinical study of an intravenous formulation of AP-188 (DMT).

AGNPF is a Canadian clinical stage pharmaceutical development company and has been approved to move forward.

The CEO stated, “The sooner we can finalize the correct dose and the optimum exposure period, the faster we can move into Phase 2 studies where we can test DMT on patients that have suffered a serious brain injury.”

https://www.algernonpharmaceuticals.com/news-media/news-releases/detail/180/algernon-neuroscience-announces-successful-dosing-of-2nd

<< Previous

Bullboard Posts

Next >>

The investment impact of the U.S. 25% tariff on Canadian imports